Minireview: Therapeutic potential of myricetin in diabetes mellitus

Food Science and Human Wellness

Volumn 1, Issue 1, 2012, Pages 19-25

  Li, Yong ^a   Ding, Ye ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Diabetes mellitus; Diabetic complications; Myricetin

Indexed keywords

EID: 85068967615     PISSN: None     EISSN: 22134530     Source Type: Journal    
DOI: 10.1016/j.fshw.2012.08.002     Document Type: Review

References (69)

1. Whiting, D.R., Guariguata, L., Weil, C., Shaw, J., IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 94 (2011), 311–321.
2. Jeffcoate, S.L., Diabetes control and complications: the role of glycated haemoglobin 25 years on. Diabet. Med. 21 (2004), 657–665.
3. Harnly, J.M., Doherty, R.F., Beecher, G.R., Holden, J.M., Haytowitz, D.B., Bhagwat, S., Gebhardt, S., Flavonoid content of US fruits, vegetables, and nuts. J. Agric. Food Chem. 54 (2006), 9966–9977.
4. Lin, J., Zhang, S.M., Wu, K., Willett, W.C., Fuchs, C.S., Giovannucci, E., Flavonoid intake and colorectal cancer risk in men and women. Am. J. Epidemiol. 164 (2006), 644–651.
5. Kim, D.O., Lee, C.Y., Comprehensive study on vitamin C equivalent antioxidant capacity (VCEAC) of various polyphenolics in scavenging a free radical and its structural relationship. Crit. Rev. Food Sci. Nutr. 44 (2004), 253–273.
6. Chen, Z.Y., Chan, P.T., Ho, K.Y., Fung, K.P., Wang, J., Antioxidant activity of natural flavonoids is governed by number and location of their aromatic hydroxyl groups. Chem. Phys. Lipids 79 (1996), 157–163.
7. Mira, L., Fernandez, M.T., Santos, M., Rocha, R., Florencio, M.H., Jennings, K.R., Interactions of flavonoids with iron and copper ions; a mechanism for their antioxidant activity. Free Radic. Res. 36 (2002), 1199–1208.
8. Kang, N.J., Jung, S.K., Lee, K.W., Lee, H.J., Myricetin is a potent chemopreventive phytochemical in skin carcinogenesis. Ann. N. Y. Acad. Sci. 1229 (2011), 124–132.
9. Shimmyo, Y., Kihara, T., Akaike, A., Niidome, T., Sugimoto, H., Three distinct neuroprotective functions of myricetin against glutamate-induced neuronal cell death; involvement of direct inhibition of caspase-3. J. Neurosci. Res. 86 (2008), 1836–1845.
10. Knekt, P., Kumpulainen, J., Jarvinen, R., Rissanen, H., Heliovaara, M., Reunanen, A., Hakulinen, T., Aromaa, A., Flavonoid intake and risk of chronic diseases. Am. J. Clin. Nutr. 76 (2002), 560–568.
11. Cushnie, T.P., Lamb, A.J., Antimicrobial activity of flavonoids. Int. J. Antimicrob. Agents 26 (2005), 343–356.
12. Gray, A.M., Flatt, P.R., Nature's own pharmacy; the diabetes perspective. Proc. Nutr. Soc. 56 (1997), 507–517.
13. Barbosa-Filho, J.M., Vasconcelos, T.H.C., Alencar, A.A., Batista, L.M., Oliveira, R.A.G., Guedes, D.N., Falcão, H.S., Moura, M.D., Diniz, M.F.F.M., Modesto-Filho, J., Plants and their active constituents from South, Central, and North America with hypoglycemic activity. Rev. Bras. Farmacogn. 15 (2005), 392–413.
14. Mendez, J., Bilia, A.R., Morelli, I., Phytochemical investigations of Licania genus. Flavonoids and triterpenoids from Licania pittieri. Pharm. Acta Helv. 70 (1995), 223–226.
15. M.J. Ahrens, D.L. Thompson, Composition and method for treating diabetes and metabolic disorders. United States Patent Application Publication 2011. US 2011/0118345 A1.
16. M.A. Mazed, S. Mazed, Nutritional supplement for the prevention of cardiovascular disease, Alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance. United States Patent Application Publication 2009. US 2009/0252796 A1.
17. Song, Y., Manson, J.E., Buring, J.E., Sesso, H.D., Liu, S., Associations of dietary flavonoids with risk of type 2 diabetes, and markers of insulin resistance and systemic inflammation in women: a prospective study and cross-sectional analysis. J. Am. Coll. Nutr. 24 (2005), 376–384.
18. Liu, I.M., Liou, S.S., Lan, T.W., Hsu, F.L., Cheng, J.T., Myricetin as the active principle of Abelmoschus moschatus to lower plasma glucose in streptozotocin-induced diabetic rats. Planta Med. 71 (2005), 617–621.
19. Ong, K.C., Khoo, H.E., Effects of myricetin on glycemia and glycogen metabolism in diabetic rats. Life Sci. 67 (2000), 1695–1705.
20. Kwon, O., Eck, P., Chen, S., Corpe, C.P., Lee, J.H., Kruhlak, M., Levine, M., Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J. 21 (2007), 366–377.
21. Liu, I.M., Tzeng, T.F., Liou, S.S., Lan, T.W., Myricetin, a naturally occurring flavonol, ameliorates insulin resistance induced by a high-fructose diet in rats. Life Sci. 81 (2007), 1479–1488.
22. Liu, I.M., Tzeng, T.F., Liou, S.S., Lan, T.W., Improvement of insulin sensitivity in obese Zucker rats by myricetin extracted from Abelmoschus moschatus. Planta Med. 73 (2007), 1054–1060.
23. Tzeng, T.F., Liou, S.S., Liu, I.M., Myricetin ameliorates defective post-receptor insulin signaling via beta-endorphin signaling in the skeletal muscles of fructose-fed rats. Evid. Based Complem. Alternat. Med. 2011 (2011), 150–152.
24. Ding, Y., Dai, X.Q., Zhang, Z.F., Li, Y., Myricetin attenuates hyperinsulinemia-induced insulin resistance in skeletal muscle cells. Eur. Food Res. Technol. 234 (2012), 873–881.
25. Ong, K.C., Khoo, H.E., Insulinomimetic effects of myricetin on lipogenesis and glucose transport in rat adipocytes but not glucose transport translocation. Biochem. Pharmacol. 51 (1996), 423–429.
26. Watanabe, T., Kondo, K., Oishi, M., Induction of in vitro differentiation of mouse erythroleukemia cells by genistein, an inhibitor of tyrosine protein kinases. Cancer Res. 51 (1991), 764–768.
27. Strobel, P., Allard, C., Perez-Acle, T., Calderon, R., Aldunate, R., Leighton, F., Myricetin, quercetin and catechin-gallate inhibit glucose uptake in isolated rat adipocytes. Biochem. J. 386 (2005), 471–478.
28. Hotamisligil, G.S., Inflammation and metabolic disorders. Nature 444 (2006), 860–867.
29. Kang, B.Y., Kim, S.H., Cho, D., Kim, T.S., Inhibition of interleukin-12 production in mouse macrophages via decreased nuclear factor-kappaB DNA binding activity by myricetin, a naturally occurring flavonoid. Arch. Pharm. Res. 28 (2005), 274–279.
30. Lee, Y.S., Choi, E.M., Myricetin inhibits IL-1beta-induced inflammatory mediators in SW982 human synovial sarcoma cells. Int. Immunopharmacol. 10 (2010), 812–814.
31. Blonska, M., Czuba, Z.P., Krol, W., Effect of flavone derivatives on interleukin-1beta (IL-1beta) mRNA expression and IL-1beta protein synthesis in stimulated RAW 264.7 macrophages. Scand. J. Immunol. 57 (2003), 162–166.
32. Kim, J.E., Kwon, J.Y., Lee, D.E., Kang, N.J., Heo, Y.S., Lee, K.W., Lee, H.J., MKK4 is a novel target for the inhibition of tumor necrosis factor-alpha-induced vascular endothelial growth factor expression by myricetin. Biochem. Pharmacol. 77 (2009), 412–421.
33. Tsai, S.H., Liang, Y.C., Lin-Shiau, S.Y., Lin, J.K., Suppression of TNF-α-mediated NF-κB activity by myricetin and other flavonoids through down-regulating the activity of IKK in ECV304 cells. J. Cell. Biochem. 74 (1999), 606–615.
34. Cao, Y., Cao, R., Brakenhielm, E., Antiangiogenic mechanisms of diet-derived polyphenols. J. Nutr. Biochem. 13 (2002), 380–390.
35. Kuo, P.L., Myricetin inhibits the induction of anti-Fas IgM-, tumor necrosis factor-alpha- and interleukin-1beta-mediated apoptosis by Fas pathway inhibition in human osteoblastic cell line MG-63. Life Sci. 77 (2005), 2964–2976.
36. de Prati, A.C., Ciampa, A.R., Cavalieri, E., Zaffini, R., Darra, E., Menegazzi, M., Suzuki, H., Mariotto, S., STAT1 as a new molecular target of anti-inflammatory treatment. Curr. Med. Chem. 12 (2005), 1819–1828.
37. Cottet, S., Dupraz, P., Hamburger, F., Dolci, W., Jaquet, M., Thorens, B., SOCS-1 protein prevents Janus Kinase/STAT-dependent inhibition of beta cell insulin gene transcription and secretion in response to interferon-gamma. J. Biol. Chem. 276 (2001), 25862–25870.
38. Suk, K., Kim, S., Kim, Y.H., Kim, K.A., Chang, I., Yagita, H., Shong, M., Lee, M.S., IFN-gamma/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic beta cell death. J. Immunol. 166 (2001), 4481–4489.
39. Banes, A.K., Shaw, S., Jenkins, J., Redd, H., Amiri, F., Pollock, D.M., Marrero, M.B., Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am. J. Physiol. Renal Physiol. 286 (2004), F653–F659.
40. Abidov, M., Ramazanov, A., Jimenez, D.R.M., Chkhikvishvili, I., Effect of Blueberin on fasting glucose, C-reactive protein and plasma aminotransferases, in female volunteers with diabetes type 2; double-blind, placebo controlled clinical study. Georgian Med. News, 2006, 66–72.
41. Ding, Y., Zhang, Z.F., Dai, X.Q., Li, Y., Myricetin protects against cytokine-induced cell death in RIN-m5f beta cells. J. Med. Food 15 (2012), 733–740.
42. Cheng, X., Siow, R.C., Mann, G.E., Impaired redox signaling and antioxidant gene expression in endothelial cells in diabetes: a role for mitochondria and the nuclear factor-E2-related factor 2-Kelch-like ECH-associated protein 1 defense pathway. Antioxid. Redox Signal. 14 (2011), 469–487.
43. Gordon, M.H., Roedig-Penman, A., Antioxidant activity of quercetin and myricetin in liposomes. Chem. Phys. Lipids 97 (1998), 79–85.
44. Panickar, K., Polansky, M., Anderson, R., Myricetin and quercetin attenuate ischemic injury in glial cultures by different mechanisms. Society for Neuroscience Abstracts and Proceedings, 2009.
45. Aherne, S.A., O'Brien, N.M., Protection by the flavonoids myricetin, quercetin, and rutin against hydrogen peroxide-induced DNA damage in Caco-2 and Hep G2 cells. Nutr. Cancer 34 (1999), 160–166.
46. Wang, L., Liu, F., Lu, J., Liu, Y., Yang, B., Effect of flavonols on caspase-3, Bcl-2 and Bax expression in cardiomyocytes apoptosis. Chin. Pharm. J. 42 (2007), 49–53 (in Chinese).
47. Lee, K.H., Choi, E.M., Myricetin, a naturally occurring flavonoid, prevents 2-deoxy-D-ribose induced dysfunction and oxidative damage in osteoblastic MC3T3-E1 cells. Eur. J. Pharmacol. 591 (2008), 1–6.
48. Zhang, K., Ma, Z., Wang, J., Xie, A., Xie, J., Myricetin attenuated MPP(+)-induced cytotoxicity by anti-oxidation and inhibition of MKK4 and JNK activation in MES23.5 cells. Neuropharmacology 61 (2011), 329–335.
49. Pandey, K.B., Mishra, N., Rizvi, S.I., Myricetin may provide protection against oxidative stress in type 2 diabetic erythrocytes. Z. Naturforsch. C 64 (2009), 626–630.
50. Rostoka, E., Baumane, L., Isajevs, S., Line, A., Dzintare, M., Svirina, D., Sharipova, J., Silina, K., Kalvinsh, I., Sjakste, N., Effects of kaempferol and myricetin on inducible nitric oxide synthase expression and nitric oxide production in rats. Basic Clin. Pharmacol. Toxicol. 106 (2010), 461–466.
51. Kaneko, M., Bucciarelli, L., Hwang, Y.C., Lee, L., Yan, S.F., Schmidt, A.M., Ramasamy, R., Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann. N. Y. Acad. Sci. 1043 (2005), 702–709.
52. Williamson, J.R., Chang, K., Frangos, M., Hasan, K.S., Ido, Y., Kawamura, T., Nyengaard, J.R., den Enden, M., Kilo, C., Tilton, R.G., Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42 (1993), 801–813.
53. Lal, S., Randall, W.C., Taylor, A.H., Kappler, F., Walker, M., Brown, T.R., Szwergold, B.S., Fructose-3-phosphate production and polyol pathway metabolism in diabetic rat hearts. Metabolism 46 (1997), 1333–1338.
54. Kawanishi, K., Ueda, H., Moriyasu, M., Aldose reductase inhibitors from the nature. Curr. Med. Chem. 10 (2003), 1353–1374.
55. Haraguchi, H., Kanada, M., Fukuda, A., Naruse, K., Okamura, N., Yagi, A., An inhibitor of aldose reductase and sorbitol accumulation from Anthocepharus chinensis. Planta Med. 64 (1998), 68–69.
56. Lim, S.S., Jung, Y.J., Hyun, S.K., Lee, Y.S., Choi, J.S., Rat lens aldose reductase inhibitory constituents of Nelumbo nucifera stamens. Phytother. Res. 20 (2006), 825–830.
57. Peyroux, J., Sternberg, M., Advanced glycation endproducts (AGEs); pharmacological inhibition in diabetes. Pathol. Biol. (Paris) 54 (2006), 405–419.
58. Matsuda, H., Wang, T., Managi, H., Yoshikawa, M., Structural requirements of flavonoids for inhibition of protein glycation and radical scavenging activities. Bioorg. Med. Chem. 11 (2003), 5317–5323.
59. Ghaffari, M.A., Mojab, S., Influence of flavonols as in vitro on low density lipoprotein glycation. Iran. Biomed. J. 11 (2007), 185–191.
60. Urios, P., Grigorova-Borsos, A.M., Sternberg, M., Flavonoids inhibit the formation of the cross-linking AGE pentosidine in collagen incubated with glucose, according to their structure. Eur. J. Nutr. 46 (2007), 139–146.
61. Dunn, F.L., Hyperlipidemia in diabetes mellitus. Diabetes Metab. Rev. 6 (1990), 47–61.
62. Liang, T., Wang, Y., Zhang, C., Ling, H., Zhao, S., Fang, X., Hypolipidemic effect of myricetin. Chin. J. Lab. Diagn. 13 (2009), 1670–1672 (in Chinese).
63. Godse, S., Mohan, M., Kasture, V., Kasture, S., Effect of myricetin on blood pressure and metabolic alterations in fructose hypertensive rats. Pharm. Biol. 48 (2010), 494–498.
64. Borde, P., Mohan, M., Kasture, S., Effect of myricetin on deoxycorticosterone acetate (DOCA)-salt-hypertensive rats. Nat. Prod. Res. 25 (2011), 1549–1559.
65. Tarling, C.A., Woods, K., Zhang, R., Brastianos, H.C., Brayer, G.D., Andersen, R.J., Withers, S.G., The search for novel human pancreatic alpha-amylase inhibitors; high-throughput screening of terrestrial and marine natural product extracts. Chembiochem 9 (2008), 433–438.
66. Zraika, S., Hull, R.L., Verchere, C.B., Clark, A., Potter, K.J., Fraser, P.E., Raleigh, D.P., Kahn, S.E., Toxic oligomers and islet beta cell death; guilty by association or convicted by circumstantial evidence. Diabetologia 53 (2010), 1046–1056.
67. Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S., Iwatsubo, T., Goedert, M., Hasegawa, M., Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280 (2005), 7614–7623.
68. Lyketsos, C.G., Depression and diabetes; more on what the relationship might be. Am. J. Psychiatry 167 (2010), 496–497.
69. Kelsey, J.E., Treatment of chronic depression. JAMA 275 (1996), 1883–1884.